A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels

Part of paid clinical trials in Brooklyn, Maryland.

Sponsor
AstraZeneca
Study ID
NCT07423598
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • AZD0780 — DRUG
    AZD0780 will be administered orally.
  • Placebo — DRUG
    Placebo will be administered orally.

Study Details

The purpose of this study is to evaluate pharmacodynamics (PD) of AZD0780 compared with placebo by assessment of low-density lipoprotein-cholesterol (LDL-C) levels following repeated oral dosing in healthy adults with elevated LDL-C levels.

Key Dates

Start date
Feb 24, 2026
Status verified
Apr 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
40 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: AZD0780
    Participants will receive a dose of AZD0780.
  • Placebo Comparator: Placebo
    Participants will receive a dose of matching placebo to AZD0780

Primary Outcome Measure

Relative change from baseline in LDL-C levels [ Time Frame: From Baseline (Day 1) to 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Research SiteBrooklynMaryland21225-

Find similar trials in Brooklyn, MD

By research site
Research Site· Brooklyn, MD

Related Studies